The incidence and risk factors of stroke in patients with acute myocardial infarction treated invasively and concomitant impaired renal function by Podolecki, Tomasz et al.
Address for correspondence: Tomasz Podolecki, MD, Department of Cardiology, Congenital Heart Diseases and  
Electrotherapy, Silesian Medical University, Silesian Center for Heart Diseases, ul. Szpitalna 2, 41–800 Zabrze, Poland,  
tel: +48 32 373 36 82, fax: +48 32 373 37 92, e-mail: tomekpod@interia.pl
Received: 27.02.2013 Accepted: 07.04.2013
original article
Cardiology Journal 
2013, Vol. 20, No. 6, pp. 672–678
DOI: 10.5603/CJ.a2013.0050 
Copyright © 2013 Via Medica
ISSN 1897–5593
672 www.cardiologyjournal.org
The incidence and risk factors of stroke in patients 
with acute myocardial infarction treated invasively 
and concomitant impaired renal function
Tomasz Podolecki1, Radosław Lenarczyk1, Jacek Kowalczyk1,  
Andrzej Świątkowski1, Piotr Chodór1, Patrycja Pruszkowska-Skrzep1,  
Agnieszka Sędkowska1, Lech Poloński2, Zbigniew Kalarus1
1Department of Cardiology, Congenital Heart Diseases and Electrotherapy,  
Silesian Medical University, Silesian Center of Heart Diseases, Zabrze, Poland 
23rd Department of Cardiology, Silesian Medical University,  
Silesian Center of Heart Diseases, Zabrze, Poland
Abstract
Background: Impaired renal function is a marker of poor prognosis in patients with acute 
myocardial infarction (AMI). The aim of the study was to assess the incidence and independent 
predictors of stroke in population of patients with AMI treated invasively and concomitant 
impaired renal function (IRF).
Methods: We analyzed 2,520 consecutive AMI patients admitted to our Center between 2003 
and 2007 and treated with percutaneous coronary intervention. The whole population was 
divided into patients with IRF, defined as glomerular filtration rate < 60 mL/min/1.73 m2 
or contrast induced nephropathy (IRF group, n = 933; 37.02%) and patients without IRF 
(control group, n = 1587; 62.98%). The IRF group was subjected to further analysis. Data on 
long-term follow-up were screened to identify the patients who experienced stroke.
Results: During median of 25.5 months of follow-up 52 (2.07%) the patients experienced 
stroke — 33 (3.54%) in the IRF group and 19 (1.2%) patients in the control group. The risk 
of major adverse cardiovascular events in the IRF group, including repeated AMI (68.8 vs. 
14.9%, p < 0.001) and death (45.5 vs. 25.1%, p < 0.05) was significantly higher in patients 
with stroke. Previous stroke (HR 6.85), female gender (HR 3.13), as well as STEMI anterior 
(HR 2.55) were independent risk factors of stroke in this population.
Conclusions: Patients with AMI treated invasively and concomitant IRF were at higher risk 
of stroke occurrence in the future. Stroke was associated with poor outcome in the studied 
population. Independent predictors of stroke in patients with IRF and AMI treated invasively 
were different from commonly recognized stroke predictors. (Cardiol J 2013; 20, 6: 672–678)
Key words: stroke, impaired renal failure, myocardial infarction, percutaneous 
coronary intervention, contrast-induced nephropathy
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Introduction
Impaired renal function (IRF) is a well recog-
nized marker of poor prognosis in general popula-
tion, as well as in patients after acute myocardial 
infarction (AMI) [1–3]. Disturbed renal function is 
associated with both higher mortality and higher 
risk of other adverse cardiac events (MACE), inclu-
ding stroke [3–5]. The incidence of stroke among 
AMI survivors may approach 1.2% within 30-day 
observation and more than 2% during 12-month 
observation [6, 7]. According to Mielniczuk et al. 
[8], the risk of stroke is over 2-fold higher in AMI 
patients with concomitant IRF. Based on previously 
published studies, atrial fibrillation (AF), diabetes 
mellitus, previous stroke, advanced age, female 
gender and anterior infarction were recognized 
as stroke predictors in patients after AMI [6, 7, 9, 
10]. However, none of the above-mentioned studies 
was based on a homogenous group of consecutive 
AMI patients treated with percutaneous coronary 
intervention (PCI).
The aim of the study was to assess the inciden-
ce and independent predictors of stroke in patients 
with AMI treated invasively and burdened with 
disturbed renal function.
Methods
The analysis was conducted on the database 
of 2,520 consecutive AMI patients admitted to our 
Center between 2003 and 2007. All the patients had 
coronary angiography and subsequent PCI perfor-
med without any delay. The aim of the procedure 
was to restore TIMI grade 3 flow, with remaining 
residual stenosis of less than 30%, in the infarct-
-related artery (IRA). A single dose of oral aspirin 
(300–500 mg) and 5,000–10,000 U of intravenous 
heparin were administered to all the patients before 
coronary angiography, whereas a loading dose of 
Clopidogrel was given before stent implantation. If 
necessary, additional doses of heparin were admi-
nistered, according to the activated clotting time. 
The duration of dual anti-platelet therapy, as well 
as concomitant post-myocardial treatment were 
in line with current recommendations of cardiac 
societies [11–13].
Data concerning demographic, clinical, labo-
ratory, echocardiographic and angiographic charac-
teristics were obtained from a single-center pro-
spective cohort study of acute coronary syndromes. 
Data on remote follow-up were obtained from the 
insurer — the National Health Fund. The diagnosis 
and type of stroke in the post-AMI period were 
established based on the international classification 
of diseases (ICD-10) codes once all the follow-up 
data had been collected and analyzed. The type of 
stroke (ischemic, hemorrhagic or undetermined) 
was additionally confirmed by a review of hospital 
charts obtained from hospitals where patients 
with stroke had been admitted to. The whole AMI 
population was divided into patients with (IRF 
group, n = 933; 37.02%) and without IRF (control 
group, n = 1587; 62.98%). Subsequently the IRF 
group was subdivided into patients with stroke 
(n = 33; 3.54%) and free of stroke (n = 900; 
96.46%) during remote observation. All the data 
regarding long-term outcomes were reviewed to 
ascertain that they fulfill the predefined criteria of 
adverse cardiovascular (CV) events.
The study was approved by the local authori-
ties and all patients were asked for written infor-
med consent.
Definitions
Renal function was assessed with estimated 
glomerular filtration rate (GFR) calculated by me-
ans of the simplified Modification of Diet in Renal 
Disease formula [14].
Contrast induced nephropathy (CIN) was defi-
ned as an elevation of serum creatinine by at least 
44.2 mmol/L (0.5 mg/dL) or a 25% increase from the 
baseline value within 48 h after contrast exposure.
IRF was defined as GFR less than 60 mL/ 
/min/1.73 m2 and/or CIN during index hospitalization.
Stroke was recognized if the development of 
an acute focal neurological deficit with a duration 
of more than 24 h was documented.
Hemorrhagic stroke was diagnosed if symp-
toms/signs were associated with bleeding on the 
computed tomography (CT) scan, while ischemic 
stroke was recognized if there was no evidence 
of bleeding on the CT scan. Undetermined stroke 
was diagnosed when no CT scan was performed.
MACE was defined as a composite of death, 
non-fatal MI and repeated percutaneous or surgical 
coronary revascularization.
Statistics analysis
Continuous parameters were expressed as 
mean ± standard deviation, whilst categorical va-
riables as numbers and percentages. Comparative 
analysis between the groups was performed with 
the Student’s t-test for continuous variables and 
c2 or Fisher’s exact test, as appropriate, for dicho-
tomous parameters. Independent stroke predictors 
were identified with the multivariate Cox regre- 
ssion model and expressed as hazard ratio (HR) 
Figure 1. Kaplan-Meier curves of cumulative survival 
without stroke in the impaired renal function (IRF) popu-
lation and the control group; AMI — acute myocardial 
infarction.
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with 95% confidence interval (CI). Two Cox-pro-
portional hazards models were created to identify 
the most powerful set of independent risk factors. 
All parameters which differed significantly between 
the stroke and the non-stroke groups were con-
sidered covariates in the first regression model. 
The second model additionally incorporated factors 
commonly believed to influence the risk of stroke: 
diabetes mellitus, arterial hypertension, AF, left 
ventricular ejection fraction (LVEF) < 35%, age 
> 65 and the use of vitamin K antagonists (VKA). 
The more predictive Cox regression model (with 
higher c2 value) was subjected to further analysis. 
Cumulative proportions of patients free of stroke 
in every group were plotted as Kaplan-Meyer 
survival curves and compared with logrank tests 
between different categories. P value < 0.05 was 
considered statistically significant. The software 
package Statistica (version 6.0, StatSoft Inc., Tulsa, 
OK, USA) was used for statistical analysis.
Results
Stroke incidence
Among 933 patients with impaired renal fun-
ction 293 (31.4%) had GFR less than 60 mL/ 
/min/1.73 m2, 466 (49.95%) developed CIN and 
174 (18.65%) patients had both GFR < 60 mL/ 
/min/1.73 m2 and CIN during index hospitalization. 
During median observation of 25.5 (range: 0–57) 
months 33 patients (3.54%) experienced stroke in 
the IRF group and only 19 (1.2%) in the control 
group (p < 0.001). Patients with GFR less than 
60 mL/min/1.73 m2 additionally complicated by CIN 
had double as high risk of stroke as subjects with 
GFR < 60 mL/min/1.73 m2 without subsequent 
CIN or those who developed CIN during index 
hospitalization, but had GFR within normal range 
at baseline (6.32% vs. 2.90%, p < 0.05). The cumu-
lative survival without stroke is shown in Figures 1 
and 2. The risk of stroke was especially high during 
the first month and first year after AMI (0.54% and 
2.47%, respectively). Twenty-six patients (78.8%) 
had ischemic strokes, whilst only 5 (15.1%) strokes 
were hemorrhagic and 2 (6.1%) undetermined.
Independent predictors of stroke
Patients who experienced stroke were more 
often female, with anterior location of MI, as well 
as with history of prior stroke. The baseline charac-
teristics of both groups are summarized in Table 1. 
According to the multivariate regression model, 
prior stroke (HR 6.85), female gender (HR 3.13) 
and anterior (HR 2.55) ST elevation myocardial 
infarction (STEMI) were independent predictors 
of stroke in the analyzed population. However, the 
“conventional” stroke predictors were not found to 
be independent predictors of stroke in AMI patients 
treated invasively. The Cox proportional hazard 
model is shown in Table 2.
Study outcomes
The incidence of MACEs within 1-year and 
remote observation was significantly higher in 
patients from the stroke group. Compared with the 
control group these patients were at a higher risk of 
repeated AMI during 30-day, 12-month, as well as 
remote observation. Neither of the groups differed 
Figure 2. Cumulative probability of survival without 
stroke in particular groups of impaired renal function; 
AMI — acute myocardial infarction; GFR — glomerular 
filtration rate; CIN — contrast induced neprhropathy.
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significantly with regard to short-term and 1-year 
mortality, however, remote mortality was signifi-
cantly higher in the stroke group (45.5 vs. 25.1%, 
p < 0.05). Among 29 patients who survived stroke, 
11 (37.93%) died during long-term observation, and 
the median time interval between stroke and death 
was 16.6 (range: 0.7–38.2) months. There were no 
significant differences between the studied groups 
in the need for repeated coronary revascularization, 
neither taking into account urgent/elective nor 
Table 1. The baseline characteristics of the study groups. 
Parameter Stroke group  
(n = 33)
Non-stroke group  
(n = 900)
P
Female 21 (63.6%) 345 (38.3%) < 0.05
Age [years] 65.9 66.0 NS
Diabetes mellitus 17 (51.5%) 407 (45.2%) NS
Hypertension 23 (69.7%) 558 (62.0%) NS
Atrial fibrillation 4 (12.1%) 131 (14.6%) NS
Hyperlipidemia 18 (54.5%) 457 (50.8%) NS
Smoking 15 (45.5%) 418 (46.4%) NS
Time from presentation to PCI [h] 6.6 7.2 NS
Prior stroke 9 (27.3%) 55 (6.1%) < 0.001
Prior AMI 11 (33.3%) 214 (23.8%) NS
Previous PCI 3 (9.1%) 92 (10.2%) NS
Previous CABG 0 (0%) 31 (3.4%) NS
STEMI anterior 20 (60.6%) 344 (38.2%) < 0.05
NSTEMI 8 (24.2%) 203 (22.6%) NS
PCI non-IRA 8 (24.2%) 160 (17.8%) NS
Hematocrit on admission 39.5 40.8 NS
LVEF [%] 42.3 40.7 NS
Thrombolysis 1 (3.0%) 27 (3.0%) NS
Glycoprotein IIb/IIIa receptor inhibitors 8 (24.2%) 168 (18.7%) NS
VKA at discharge 1 (3.0%) 10 (1.1%) NS
ASA at discharge 32 (97.0%) 883 (98.1%) NS
Thienopirydine at discharge 32 (97.0%) 866 (96.2%) NS
Beta-blockers at discharge 30 (90.9%) 814 (90.4%) NS
ACE-I at discharge 29 (87.9%) 797 (88.6%) NS
Statins at discharge 29 (87.9%) 782 (86.9%) NS
ACE-I — angiotensin converting enzyme inhibitors; AMI — acute myocardial infarction; ASA — acetylsalicylic acid; CABG — coronary  
artery bypass grafting; GFR — glomerular filtration rate; IRA — infarct related artery; LVEF — left ventricular ejection fraction;  
NSTEMI — non-ST elevation myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST-elevation myocardial  
infarction; VKA — vitamin K antagonists
Table 2. Model of multivariate Cox regression.
Parameter Hazard ratio ± 95% confidence interval Wald c2 P
Female gender 3.13 (2.39–3.87) 9.13 < 0.05
Age > 65 years 1.03 (0.12–1.94) 0.01 NS
Atrial fibrillation 1.23 (0.16–2.30) 0.15 NS
Anterior STEMI 2.55 (1.80–3.30) 5.89 < 0.05
Arterial hypertension 0.75 (0–1.53) 0.50 NS
Previous stroke 6.85 (6.03–7.67) 20.70 < 0.001
Diabetes mellitus 1.13 (0.42–1.84) 0.11 NS
LVEF < 35% 0.92 (0–1.85) 0.03 NS
VKA 1.37 (0.3–2.44) 0.09 NS
LVEF — left ventricular ejection fraction; STEMI — ST-elevation myocardial infarction; VKA — vitamin K antagonists
676 www.cardiologyjournal.org
Cardiology Journal 2013, Vol. 20, No. 6
percutaneous/surgical procedures. Additionally, 
patients with stroke developed more frequently 
end-stage renal failure requiring dialysis (12.12 vs. 
2.89%, p < 0.05). The data on short- and long-term 
follow-ups are shown in Table 3.
Discussion
We have shown in our study that in AMI 
population the risk of stroke is 3-fold higher in 
subjects with concomitant IRF compared to pa-
tients with normal renal function. This observation 
was concordant with previous reports, as IRF had 
been demonstrated to be a powerful risk factor for 
CV diseases, including stroke [3–5, 8]. However, 
contrary to prior studies our analysis was con-
ducted on a homogenous AMI population treated 
invasively. This fact is an essential novelty of our 
study and may have had a significant impact on our 
results, as on the one hand PCI was proved to re-
duce the risk of stroke in AMI patients [15], and on 
the other hand contrast exposure may deteriorate 
renal function and increase CV risk associated with 
renal failure [3–5, 8].
Many distinct mechanisms have been propo-
sed to account for increased CV risk in renal dys-
function. IRF is associated with oxidative stress, 
inflammation, a state of hypercoagulation with high 
levels of von Willebrand factor, fibrinogen, factors 
VII, VIII and IX, as well as enhanced thrombin ge-
neration and decrease in fibrinolytic activity, that 
promote plaques formation and deteriorate endo-
thelial function [16, 17]. It has been also suggested, 
that vascular inflammation may be an important 
mediator of both renal dysfunction and CV risk [8]. 
Additionally, higher blood pressure, dyslipidemia, 
microalbuminuria, homocysteinemia, as well as 
elevated plasma uric acid level accelerate athero-
sclerotic process in IRF population [3]. Contrast 
induced nephropathy developing in subjects with 
primarily decreased GFR may severely deteriorate 
renal function and amplify mechanisms mentioned-
-above leading to significant increase in CV risk.
Stroke, which occurred after AMI, indepen-
dently of its timing, was a marker of heightened 
risk of death and recurrent MI during 1-year and 
remote follow-up. Our results are consistent with 
the findings from the OASIS study, which showed 
Table 3. Outcomes in patients with and without stroke after myocardial infarction.
Stroke group (n = 33) Non-stroke group (n = 900) P 
30-day outcome:
Myocardial infarction 2 (6.1%) 10 (1.1%) < 0.05
Elective PCI 0 (0%) 9 (1.0%) NS
Urgent PCI 0 (0%) 5 (0.6%) NS
Elective CABG 0 (0%) 2 (0.2%) NS
Urgent CABG 0 (0%) 1 (0.1%) NS
Mortality 2 (6.1%) 139 (15.4%) NS
MACE 3 (9.1%) 160 (17.8%) NS
One-year outcome:
Myocardial infarction 11 (33.3%) 103 (11.4%) < 0.001
Elective PCI 5 (15.2%) 84 (9.3%) NS
Urgent PCI 3 (9.1%) 35 (3.9%) NS
Elective CABG 3 (9.1%) 46 (5.1%) NS
Urgent CABG 0 (0%) 1 (0.1%) NS
Mortality 9 (27.3%) 208 (23.1%) NS
MACE 22 (66.7%) 445 (49.4%) < 0.05
Remote follow up:
Myocardial infarction 11 (33.3%) 127 (14.1%) < 0.05
Elective PCI 6 (18.2%) 104 (11.6%) NS
Urgent PCI 3 (9.1%) 47 (5.2%) NS
Elective CABG 3 (9.1%) 53 (5.9%) NS
Urgent CABG 0 (0%) 2 (0.2%) NS
Mortality 15 (45.5%) 226 (25.1%) < 0.05
MACE 25 (75.8%) 503 (55.9%) < 0.05
CABG — coronary artery bypass grafting; MACE — major adverse cardiovascular event; PCI — percutaneous coronary intervention
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that a stroke subsequent to acute coronary syn-
drome was associated with significantly higher 
mortality at 6-month follow-up (27 vs. 6.3%, 
p < 0.001) [18]. Also other studies showed stroke 
population to be at a higher risk of CV adverse 
events [19, 20]. Apart from its direct impact on 
mortality, the stroke may be a marker of severity 
of atherosclerotic process, endothelial dysfunction 
and hypercoagulation state. This hypothesis may 
partly explain a worse prognosis in patients with 
AMI who developed stroke.
We found previous stroke to be the strongest, 
independent predictor of next stroke in patients 
with AMI and concomitant IRF. It is in concordance 
with prior reports and is reasonable, as once reco - 
gnized cerebrovascular disease is still present, it 
can progress and predisposes to a new cerebrova-
scular incident [3, 6–8]. Female gender, broadly 
postulated as a stroke predictor [6], was also inde-
pendently associated with increased risk of stroke 
in AMI population with concomitant disturbed 
renal function.
Our analysis demonstrated that patients with 
anterior STEMI were at higher risk of subse-
quent stroke. The mechanisms underlying this 
predisposition are likely multifactorial. Anterior 
infarctions, usually resulting in larger necrotic 
area, may essentially predispose to heart failure 
and left ventricular thrombus formation [21, 22]. 
These factors might be also associated with incre-
ased predisposition to stroke in our group, as we 
observed significantly higher maximal values of 
MB isoenzyme of creatine kinase and lower LVEF 
in subjects with anterior STEMI than in patients 
with STEMI of other locations.
As opposed to previous studies [6, 9, 15, 19], 
we did not find AF to increase the risk of stroke 
in the studied population. One of possible expla-
nations for it might be the fact, that over 95% of 
patients in our population were treated with dual 
anti-platelet therapy, whereas in prior studies 
monotherapy with acetylsalicylic acid (ASA) was 
mostly applied [6, 9, 15, 19]. Our hypothesis is sup-
ported by the findings from the ACTIVE study, as 
according to them double anti-platelet therapy was 
proved to be more effective than ASA monotherapy 
in stroke prevention in AF population [23, 24]. Ad-
ditionally, dual anti-platelet therapy was reported 
to be of equal effectiveness in stroke prophylaxis 
as oral VKA in patients with newly administered 
VKA therapy [23, 24]. Therefore, combined therapy 
with ASA and thienopyridine may weaken the pro-
-thrombotic effect of AF, and hence may reduce the 
risk of ischemic stroke in the studied population.
The beneficial impact of renin–angiotensin 
system blockade on the risk of adverse CV events 
after AMI, especially in patients with chronic kid-
ney disease, has been already demonstrated [5, 15, 
25]. In our population the rate of patients receiving 
angiotensin converting enzyme inhibitor (ACE-I) 
or angiotensin receptor blockers (ARB) exceede-
ds 85% and was significantly higher than in prior 
studies. The high rate of ACE-I/ARB recipients 
and aggressive treatment of arterial hypertension 
might partially explain the lack of unfavorable effect 
of arterial hypertension on the risk of stroke in our 
study. In contrast to the majority of prior studies, 
heart failure was not associated significantly with 
the increased risk of stroke in the examined popu-
lation [6, 15]. Our findings were consistent with the 
results of the VALIANT study, which demonstrated 
that decreased LVEF was not predictive of stroke 
in high-risk patients after AMI [15]. We suppose 
that complex pharmacotherapy, by a variety of me-
chanisms, including: plaque stabilization, reduction 
in endothelial dysfunction, preventing ventricular 
remodeling and thrombus formation, could attenu-
ate the negative effect of heart failure on the risk 
of stroke after MI [15, 24, 26].
Our results suggest that diabetes mellitus does 
not increase significantly the risk of stroke in AMI 
population with IRF. The strict glycemia control and 
intensive insulinotherapy administered in an early 
peri-infarct period could partially account for attenu-
ation of risk associated with hyperglycemia status. 
The prothrombotic platelet and plasma properties 
in subjects with diabetes mellitus may be reduced 
thanks to achieving lower blood glucose levels that 
additionally could beneficially influence the lipid 
profile and endothelial function [27]. Our hypothesis 
is supported by findings from the DIGAMI II study, 
as stricter diabetes control was demonstrated to 
beneficially influence the risk of CV adverse events, 
including stroke, in subjects after AMI [28].
We suppose that in patients with AMI and con-
comitant impaired renal function early invasive tre-
atment and routine complex pharmacotherapy may 
reduce the risk of stroke, as well as attenuate the 
significance of “conventional” stroke predictors, 
and simultaneously increase the role of other risk 
factors, nevertheless, further research is needed.
Limitations of the study
All analyses were based on observational data, 
with all the drawbacks associated with data collec-
ted this way. Because of the relatively small po-
pulation and low number of neurological incidents 
during follow-up, some important parameters, 
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influencing the risk of stroke, might have been 
underestimated. Therefore, our results should be 
considered hypothesis generating data.
Conclusions
The patients treated invasively in the acute 
phase of MI, with concomitant impaired renal fun-
ction, are at higher risk of stroke, especially within 
the early post-AMI period. The population with 
primarily decreased GFR and overlapping contrast 
induced nephropathy is the group of extremely 
high CV risk. The independent risk factors for 
stroke in patients with IRF and AMI treated with 
PCI are only partially consistent with commonly 
recognized stroke predictors. The stroke ought 
to be considered a significant marker of worse 
prognosis after MI.
Conflict of interest: none declared
References
 1.  Go AS, Yang J, Ackerson LM et al. Hemoglobin level, chronic 
kidney disease, and the risks of death and hospitalization in 
adults with chronic heart failure: the Anemia in Chronic Heart 
Failure: Outcomes and Resource Utilization (ANCHOR) Study. 
Circulation, 2006; 113: 271–223.
 2.  Ezekowitz J, McAlister FA, Humphries KH et al.; APPROACH 
Investigators. The association among renal insufficiency, pharma-
cotherapy and outcomes in 6,427 patients with heart failure and 
coronary artery disease. J Am Coll Cardiol, 2004; 44: 1587–1592.
 3.  Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between 
renal dysfunction and cardiovascular outcomes after myocardial 
infarction. N Engl J Med, 2004; 35: 1285–1295.
 4.  Gibson CM, Pinto DS, Murphy SA et al; TIMI Study Group 
(2003) Association of creatinine and creatinine clearance on pre-
sentation in acute myocardial infarction with subsequent morta-
lity. J Am Coll Cardiol, 2003; 42: 1535–1543.
 5.  Tokmakova MP, Skali H, Kenchaiah S et al. Chronic kidney 
disease, cardiovascular risk, and response to angiotensin-conver-
ting enzyme inhibition after myocardial infarction: the Survival 
And Ventricular Enlargement (SAVE) study. Circulation, 2004; 
110: 3667–3673.
 6.  Witt BJ, Ballman KV, Brown RD Jr, Meverden RA, Jacobsen SJ, 
Roger VL. The incidence of stroke after myocardial infarction: 
A meta-analysis. Am J Med, 2006; 119: 354.e1-9.
 7.  Herlitz J, Holm J, Peterson M, Karlson BW, Evander MH, Erhardt L; 
LoWASA Study Group. Factors associated with development of 
stroke long-term after myocardial infarction: experiences from 
the LoWASA trial. J Intern Med, 2005; 257: 201–207. 
 8.  Mielniczuk LM, Pfeffer MA, Lewis EF et al. Estimated glomeru-
lar filtration rate, inflammation, and cardiovascular events after 
an acute coronary syndrome. Am Heart J, 2008; 155: 725–731. 
 9.  Mooe T, Eriksson P, Stegmayr B. Ischemic stroke after acute 
myocardial infarction. A population-based study. Stroke, 1997; 
28: 762–767.
 10.  Loh E, Sutton MS, Wun CC et al. Ventricular dysfunction and the 
risk of stroke after myocardial infarction. N Engl J Med, 1997; 
336: 251–257.
 11.  Bertrand ME, Simoons ML, Fox KA et al. Management of acute 
coronary syndromes in patients presenting without persistent 
ST-segment elevation. Eur Heart J, 2002; 23: 1809–1840.
 12.  Van de Werf F, Ardissino D, Betriu A et al. Management of acute 
myocardial infarction in patients presenting with ST-segment 
elevation. The Task Force on the Management of Acute Myocar-
dial Infarction of the European Society of Cardiology. Eur Heart J, 
2003; 24: 28–66.
 13.  Silber S, Albertsson P, Avilés FF et al. Guidelines for percuta-
neous coronary interventions. The Task Force for Percutaneous 
Coronary Interventions of the European Society of Cardiology. 
Eur Heart J, 2005; 26: 804–847.
 14.  Levey AS, Coresh J, Balk E et al.; National Kidney Foundation. 
National Kidney Foundation practice guidelines for chronic kid-
ney disease: evaluation, classification, and stratification. Ann 
Intern Med, 2003; 139: 137–147. 
 15.  Sampson UK, Pfeffer MA, McMurray JJ, Lokhnygina Y, White HD, 
Solomon SD; VALIANT Trial Investigators. Predictors of stroke 
in high-risk patients after acute myocardial infarction: insights 
from the VALIANT Trial. Eur Heart J, 2007; 28: 685–691.
 16.  Gibson CM, Dumaine RL, Gelfand EV et al; TIMI Study Group. 
Association of glomerular filtration rate on presentation with 
subsequent mortality in non-ST-segment elevation acute corona-
ry syndrome: Observations in 13 307 patients in five TIMI trials. 
Eur Heart J, 2004; 25: 1998–2005.
 17.  Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, 
Stehouwer CD. Impaired renal function is associated with mar-
kers of endothelial dysfunction and increased inflammatory acti-
vity. Nephrol Dial Transplant, 2003; 18: 892–898.
 18.  Cronin L, Mehta SR, Zhao F et al. Stroke in relation to cardiac 
procedures in patients with non-ST-elevation acute coronary 
syndrome: a study involving > 18 000 patients. Circulation, 
2001; 104: 269–274.
 19.  Tanne D, Goldbourt U, Zion M, Reicher-Reiss H, Kaplinsky E, 
Behar S. Frequency and prognosis of stroke/TIA among 4808 
survivors of acute myocardial infarction. The SPRINT Study 
Group. Stroke, 1993; 24: 1490–1495.
 20.  Szummer KE, Solomon SD, Velazquez EJ et al.; VALIANT Regi-
stry. Heart failure on admission and the risk of stroke following 
acute myocardial infarction: The VALIANT registry. Eur Heart J, 
2005; 26: 2114–2119.
 21.  Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular thrombus 
formation after first anterior wall acute myocardial infarction. Am 
J Cardiol, 1988; 62: 31–35.
 22.  Vaitkus PT, Barnathan ES. Embolic potential, prevention and 
management of mural thrombus complicating anterior myocar-
dial infarction: a meta-analysis. J Am Coll Cardiol, 1993; 22: 
1004–1009.
 23.  Healey JS, Hart RG, Pogue J et al. Risks and benefits of oral an-
ticoagulation compared with clopidogrel plus aspirin in patients 
with atrial fibrillation according to stroke risk: the atrial fibrilla-
tion clopidogrel trial with irbesartan for prevention of vascular 
events (ACTIVE-W). Stroke, 2008; 39: 1482–1486.
 24.  Connolly SJ, Pogue J, Hart RG et al.; ACTIVE Investigators. 
Effect of clopidogrel added to aspirin in patients with atrial fibril-
lation. N Engl J Med, 2009; 360: 2066–2078.
 25.  Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Ef-
fects of an angiotensin-converting-enzyme inhibitor, ramipril, on 
cardiovascular events in high-risk patients. The Heart Outcomes 
Prevention Evaluation Study Investigators. N Engl J Med, 2000; 
342: 145–153.
 26.  Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, sta-
tins, and cholesterol. A meta-analysis of randomized, placebo-
-controlled, double-blind trials with HMG-CoA reductase inhibi-
tors. Stroke, 1997; 28: 946–950. 
 27.  Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, 
Wedel H. Effects of insulin treatment on cause-specific one-
-year mortality and morbidity in diabetic patients with acute 
myocardial infarction. DIGAMI Study Group. Diabetes Insulin-
-Glucose in Acute Myocardial Infarction. Eur Heart J, 1996; 17: 
1337–1344.
 28.  Malmberg K, Rydén L, Wedel H et al.; DIGAMI 2 Investigators. 
Intense metabolic control by means of insulin in patients with 
diabetes mellitus and acute myocardial infarction (DIGAMI 2): 
effects on mortality and morbidity. Eur Heart J, 2005; 26: 
650–661.
